济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议

智通财经02-02

智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608676850?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-02 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608676850","market":"us","top_or_hot":-1,"title":"济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400643.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 18:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1400643.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400643.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1400643.html","article_id":"2608676850","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608676850","pubTimestamp":1770027475,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有完全知识产权的JAK1/2抑制剂，用于治疗过敏性鼻炎。交易完成后，公司将进一步加强产品线的丰富程度，有利于公司业务的可持续发展。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","600566":"济川药业","09939":"开拓药业-B","BK0188":"融资融券","BK1515":"抗疫概念","BK1161":"生物科技","BK0012":"证金概念","BK1574":"生物医药B类股","BK0077":"质押式回购","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0201":"可转债"},"translate_title":"A subsidiary of Jichuan Pharmaceutical (600566. SZ) signed an exclusive commercialization cooperation agreement with Puqi Pharmaceutical","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"600566":1.5,"09939":1.5},"content_text":"智通财经APP讯，济川药业(600566.SZ)公告，公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示，普美昔替尼(PG-011)是一款自主研发、具有完全知识产权的JAK1/2抑制剂，用于治疗过敏性鼻炎。交易完成后，公司将进一步加强产品线的丰富程度，有利于公司业务的可持续发展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608676850","isCrawlerRequest":true}